BIIB | Biogen

211.93 0.55 (0.26%)

BIIB Price Profile

Open

$211.38

CLOSE

$211.93

DAY RANGE

207.19 - 212.71

52 WEEK RANGE

187.16 - 372.12

MARKET CAP

32.9B

Trading volume

2.95M

Prev. Close

211.38

50 Day MA

238.71

Shares Outstanding

146.89M

Public Float

146.49M

Average Volume

2.25M

Beta

0.42

PEG Ratio

-1.82

Shares Shorted

2.46M

% OF SHARES SHORTED

1.89%

Short Ratio

1.41

1 Year Performance

-16.16%

Diluted EPS (TTM)

10.22

Q Revenue Growth

-0.18

Ebitda

3.02B

Gross Profit (TTM)

11.64B

Total Cash (MRQ)

2.96B

Total Debt (MRQ)

7.62B

  • MRQ = Most Recent Quarter.
  • TTM = Trailing Twelve Months.

Biogen (BIIB) company profile

Biogen Inc. (NASDAQ: BIIB) is a biopharmaceutical company that discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative conditions. The company’s products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA used in multiple sclerosis treatment; SPINRAZA for treating spinal muscular atrophy; and FUMADERM for severe plaque psoriasis. The company has a global client reach.

Latest BIIB News

AD